Eli Lilly
NICE recommends Lilly’s Emgality for chronic and episodic migraine
November 18, 2020Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK
Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …
US reserves 300,000 doses of Lilly’s COVID-19 treatment in $375 million deal
October 28, 2020Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Eli Lilly, US, pharma
The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its …
Eli Lilly refutes FDA quality concerns at New Jersey facility producing COVID-19 drug
October 21, 2020Manufacturing and Production, Research and Development COVID-19, Eli Lilly, FDA, pharma
Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it …
Eli Lilly COVID-19 antibody therapy trial paused over safety concerns
October 14, 2020Research and Development COVID, Eli Lilly, coronavirus
Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns. …
Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations
October 8, 2020Manufacturing and Production Eli Lilly, FDA
Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data
September 15, 2020Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …
Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3
July 30, 2020Research and Development Boehringer, Eli Lilly, jardiance, pharma
Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …
Eli Lilly teams up with Chi-Med for Chinese sales of Elunate capsules
July 28, 2020Manufacturing and Production, Sales and Marketing Chi-Med, China, Eli Lilly
Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or …
Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis
July 24, 2020Medical Communications Eli Lilly, Humalog, diabetes, insulin
Insulin manufacturer Eli Lilly has requested a $24 million tax break over the next 10 years as an investment into …
Eli Lilly will limit insulin costs to $35 per month for patients in the US due to COVID-19
April 8, 2020Research and Development Eli Lilly, diabetes, insulin
Eli Lilly announced that it will limit out of pocket costs for insulin to $35 per month to offset the …
Lilly partners with Sitryx in $880m immunometabolism drug development deal
April 1, 2020Research and Development Eli Lilly, Sitryx, partnership, pharma
Eli Lilly and UK firm Sitryx have partnered up in a new drug development and commercialisation deal that could potentially …
COVID-19: Gilead freezes compassionate access to remdesivir due to “overwhelming demand”, BMS and Lilly delay new study launches
March 24, 2020Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, Eli Lilly, Gilead, Roche, cornavirus, pharma
As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and …
Coronavirus forcing Eli Lilly employees to work from home
March 9, 2020Sales and Marketing Chinese Coroanvirus, Eli Lilly, Eli Lilly Coronavirus, Wuhan Coronavirus, coronavirus
Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its …
FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC
February 27, 2020Sales and Marketing Eli Lilly, FDA, cyramza, pharms
Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs …
Latest content
Five Facts about cardiovascular disease
